$MEIP
MEI Pharma, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017022001070 Filed on February 10, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $18.22M $13.39M $9.167M
YoY Change 98.78% 249.17% 809.42%
Cost Of Revenue $0.00 $494.0K
YoY Change -100.0% -22.93%
Gross Profit $18.22M $13.39M $8.673M
YoY Change 110.1% 302.62% 2263.22%
Gross Profit Margin 100.0% 100.0% 94.61%
Selling, General & Admin $7.926M $7.909M $5.650M
YoY Change 40.28% 33.6% 34.52%
% of Gross Profit 43.5% 59.08% 65.14%
Research & Development $21.53M $19.95M $22.22M
YoY Change -3.12% 53.53% 168.37%
% of Gross Profit 118.16% 149.05% 256.24%
Depreciation & Amortization $75.00K $77.00K $70.00K
YoY Change 7.14% 11.59% 133.33%
% of Gross Profit 0.41% 0.58% 0.81%
Operating Expenses $21.53M $19.95M $22.22M
YoY Change -3.12% 53.53% 168.37%
Operating Profit -$11.24M -$14.48M -$19.20M
YoY Change -41.49% -7.13% 58.57%
Interest Expense $5.469M $2.595M $7.250M
YoY Change -24.57% -80.78% -189.29%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $500.0K
YoY Change -100.0% -100.0% 3746.15%
Pretax Income -$12.16M -$17.51M -$11.45M
YoY Change 6.17% 737.8% -43.37%
Income Tax
% Of Pretax Income
Net Earnings -$12.16M -$17.51M -$8.026M
YoY Change 51.46% -2559.27% -60.3%
Net Earnings / Revenue -66.71% -130.8% -87.55%
Basic Earnings Per Share -$0.05 -$0.11 -$0.10
Diluted Earnings Per Share -$0.09 -$0.13 -$0.16
COMMON SHARES
Basic Shares Outstanding 126.7M 112.7M 112.5M
Diluted Shares Outstanding 128.2M 113.9M 114.5M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $185.8M $145.5M $180.1M
YoY Change 3.14% -17.37% 73.34%
Cash & Equivalents $12.55M $15.62M $9.877M
Short-Term Investments $173.2M $129.9M $170.3M
Other Short-Term Assets $4.823M $3.739M $3.700M
YoY Change 30.35% 86.95% 76.19%
Inventory
Prepaid Expenses
Receivables $10.15M $10.00M $10.20M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $200.7M $167.4M $194.0M
YoY Change 3.45% -17.93% 82.28%
LONG-TERM ASSETS
Property, Plant & Equipment $1.414M $1.438M $1.641M
YoY Change -13.83% -13.32% 294.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $8.739M $8.989M $9.848M
YoY Change -11.26% -10.81% 1392.12%
TOTAL ASSETS
Total Short-Term Assets $200.7M $167.4M $194.0M
Total Long-Term Assets $8.739M $8.989M $9.848M
Total Assets $209.5M $176.4M $203.9M
YoY Change 2.74% -17.6% 90.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.256M $8.472M $5.555M
YoY Change 12.62% 32.89% 82.85%
Accrued Expenses $9.765M $6.099M $11.10M
YoY Change -12.04% 10.15% 189.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.52M $30.37M $37.01M
YoY Change -17.53% -3.56% 272.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $113.5M $121.2M $93.40M
YoY Change 21.47% 20.97% 369.35%
Total Long-Term Liabilities $113.5M $121.2M $93.40M
YoY Change 21.47% 20.97% 369.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.52M $30.37M $37.01M
Total Long-Term Liabilities $113.5M $121.2M $93.40M
Total Liabilities $132.2M $144.5M $130.4M
YoY Change 1.41% 9.75% 337.23%
SHAREHOLDERS EQUITY
Retained Earnings -$345.5M -$339.7M -$290.8M
YoY Change 18.82% 21.61% 14.29%
Common Stock $422.7M $371.5M $364.3M
YoY Change 16.04% 2.73% 9.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $73.33M $34.30M $78.57M
YoY Change
Total Liabilities & Shareholders Equity $209.5M $176.4M $203.9M
YoY Change 2.74% -17.6% 90.36%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$12.16M -$17.51M -$8.026M
YoY Change 51.46% -2559.27% -60.3%
Depreciation, Depletion And Amortization $75.00K $77.00K $70.00K
YoY Change 7.14% 11.59% 133.33%
Cash From Operating Activities -$8.566M -$7.721M $4.050M
YoY Change -311.51% -15.26% -138.65%
INVESTING ACTIVITIES
Capital Expenditures -$51.00K $8.000K -$60.00K
YoY Change -15.0% -98.76% 500.0%
Acquisitions
YoY Change
Other Investing Activities -$43.32M $15.00M -$5.090M
YoY Change 751.04% 192.99% -85.58%
Cash From Investing Activities -$43.37M $14.99M -$5.150M
YoY Change 742.12% 234.96% -85.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.87M -194.0K 20.00K
YoY Change 244225.0% -105.95% -99.96%
NET CHANGE
Cash From Operating Activities -8.566M -7.721M 4.050M
Cash From Investing Activities -43.37M 14.99M -5.150M
Cash From Financing Activities 48.87M -194.0K 20.00K
Net Change In Cash -3.070M 7.078M -1.080M
YoY Change 184.26% -614.76% -140.75%
FREE CASH FLOW
Cash From Operating Activities -$8.566M -$7.721M $4.050M
Capital Expenditures -$51.00K $8.000K -$60.00K
Free Cash Flow -$8.515M -$7.729M $4.110M
YoY Change -307.18% -20.77% -139.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2028-03-31
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001262104
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50484
dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0407811
dei Entity Address Address Line1
EntityAddressAddressLine1
11455 El Camino Real
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
369-7100
dei Security12b Title
Security12bTitle
Common Stock, $0.00000002 par value
dei Trading Symbol
TradingSymbol
MEIP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
132985545
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12551000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8543000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
173200000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
144883000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
185751000
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
153426000
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
10151000
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7582000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4823000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3809000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
200725000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
164817000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7325000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7774000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1414000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1507000
CY2021Q4 us-gaap Assets
Assets
209464000
CY2021Q2 us-gaap Assets
Assets
174098000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6256000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6355000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9765000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8402000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
13515000
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14609000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
987000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
928000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30523000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30294000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
80527000
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
72717000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6855000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7370000
CY2021Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
14309000
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
22355000
CY2021Q4 us-gaap Liabilities
Liabilities
132214000
CY2021Q2 us-gaap Liabilities
Liabilities
132736000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132905000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132905000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112615000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112615000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
422705000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
369171000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345455000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-327809000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
77250000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
41362000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
209464000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
174098000
CY2021Q4 us-gaap Revenues
Revenues
18222000
CY2020Q4 us-gaap Revenues
Revenues
9167000
us-gaap Revenues
Revenues
31609000
us-gaap Revenues
Revenues
13001000
CY2021Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2020Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
494000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1003000
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21531000
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22224000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41484000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35220000
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7926000
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5650000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15835000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11565000
CY2021Q4 us-gaap Costs And Expenses
CostsAndExpenses
29457000
CY2020Q4 us-gaap Costs And Expenses
CostsAndExpenses
28368000
us-gaap Costs And Expenses
CostsAndExpenses
57319000
us-gaap Costs And Expenses
CostsAndExpenses
47788000
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11235000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19201000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25710000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34787000
CY2021Q4 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
5458000
CY2020Q4 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
7083000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
8046000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
20307000
CY2021Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
11000
CY2020Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
164000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
18000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
439000
CY2021Q4 us-gaap Interest Expense Other
InterestExpenseOther
0
CY2020Q4 us-gaap Interest Expense Other
InterestExpenseOther
500000
us-gaap Interest Expense Other
InterestExpenseOther
0
us-gaap Interest Expense Other
InterestExpenseOther
495000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-5766000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-11454000
us-gaap Net Income Loss
NetIncomeLoss
-17646000
us-gaap Net Income Loss
NetIncomeLoss
-13546000
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5766000
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11454000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17646000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13546000
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11224000
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18537000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25692000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33853000
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2020Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2020Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126725000
CY2020Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112524000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115982000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112480000
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128160000
CY2020Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114461000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
118657000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114709000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
41362000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11880000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-194000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2539000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
31827000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-5766000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3672000
CY2021Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48653000
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
212000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2324000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
77250000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
78218000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2092000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
64000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3136000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
124000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2942000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
82328000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-11454000
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2609000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
73498000
us-gaap Profit Loss
ProfitLoss
-17646000
us-gaap Profit Loss
ProfitLoss
-13546000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
8046000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
20307000
us-gaap Share Based Compensation
ShareBasedCompensation
4863000
us-gaap Share Based Compensation
ShareBasedCompensation
5551000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
152000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
143000
meip Non Cash Lease Expense
NonCashLeaseExpense
449000
meip Non Cash Lease Expense
NonCashLeaseExpense
482000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20420000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
2569000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
7026000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1014000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1268000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-99000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3118000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1363000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5012000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6716000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2334000
meip Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-456000
meip Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
26000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16287000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5061000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
700000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
173300000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
215176000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
144983000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
215208000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28376000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-668000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
194000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
212000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
139000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52325000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3200000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3672000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
64000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48671000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3275000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4008000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2454000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8543000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12331000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12551000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9877000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-8000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8689000
meip Number Of Clinical Stage Candidates
NumberOfClinicalStageCandidates
3
CY2021Q4 meip Potential Milestone Payments Payable
PotentialMilestonePaymentsPayable
20000000.0
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345500000
CY2021Q4 meip Cash And Cash Equivalentsshort Term Investments And Common Stock Proceeds Receivable
CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable
185800000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain reclassifications have been made to the prior year financial statements to conform to the current year financial statement presentation of contract assets and cash flows from financing activities. These changes did not impact previously reported net loss, loss per share, stockholders’ equity, total assets or cash flows.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates.</span></p>
CY2021Q4 us-gaap Revenues
Revenues
18222000
CY2020Q4 us-gaap Revenues
Revenues
9167000
us-gaap Revenues
Revenues
31609000
us-gaap Revenues
Revenues
13001000
CY2021Q4 us-gaap Revenues
Revenues
18222000
CY2020Q4 us-gaap Revenues
Revenues
9167000
us-gaap Revenues
Revenues
31609000
us-gaap Revenues
Revenues
13001000
meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
31600000
meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
12700000
CY2021Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
0
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128160000
CY2020Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114461000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
118657000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114709000
CY2020Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
83000
meip Receivables Amounts Billed
ReceivablesAmountsBilled
35757000
meip Receivables Amounts Billed
ReceivablesAmountsBilled
8355000
meip Receivables Payments Received
ReceivablesPaymentsReceived
-35757000
meip Receivables Payments Received
ReceivablesPaymentsReceived
-8037000
CY2021Q4 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
0
CY2020Q4 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
401000
CY2021Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7582000
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2858000
meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
38326000
meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
15381000
meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-35757000
meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-8355000
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
10151000
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
9884000
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
22781000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
17955000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6716000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2334000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
29497000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
20289000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
94000000.0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17646000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5766000
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11454000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13546000
CY2021Q4 meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-5458000
CY2020Q4 meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-7083000
meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-8046000
meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-20307000
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11224000
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18537000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25692000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33853000
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126725000
CY2020Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112524000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115982000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112480000
CY2021Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1435000
CY2020Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1937000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2675000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2229000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8689000
CY2021Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
377000
CY2020Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
377000
us-gaap Operating Lease Cost
OperatingLeaseCost
753000
us-gaap Operating Lease Cost
OperatingLeaseCost
753000
CY2021Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20689000
CY2020Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15558000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20915000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15777000
CY2020Q3 meip Initial Recognition Of Operating Lease Right Of Use Asset
InitialRecognitionOfOperatingLeaseRightOfUseAsset
8700000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8700000
CY2021Q4 meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
380000
CY2020Q4 meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
123000
meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
760000
meip Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
246000
CY2021Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020Q4 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
meip Unsold Securities Shares And Warrants Under Agreement
UnsoldSecuritiesSharesAndWarrantsUnderAgreement
107500000
CY2021Q4 meip Aggregate Value Of Securities Available Under Agreement
AggregateValueOfSecuritiesAvailableUnderAgreement
123400000
CY2021Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
14300000
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
22400000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
102047
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1778214
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
760000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1565000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1612000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1168000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1710000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1761000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1360000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9936000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2094000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7842000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
987000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6855000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7842000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
173200000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
144900000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2324000
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2609000
us-gaap Share Based Compensation
ShareBasedCompensation
4863000
us-gaap Share Based Compensation
ShareBasedCompensation
5551000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16668542
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5573734
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.93
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.13
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20362015
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3439237
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10129870
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.88
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3177213
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.680
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.808
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.30
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10900
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D

Files In Submission

Name View Source Status
0000950170-22-001070-index-headers.html Edgar Link pending
0000950170-22-001070-index.html Edgar Link pending
0000950170-22-001070.txt Edgar Link pending
0000950170-22-001070-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img102239242_0.jpg Edgar Link pending
img102239242_1.jpg Edgar Link pending
meip-20211231.htm Edgar Link pending
meip-20211231.xsd Edgar Link pending
meip-20211231_cal.xml Edgar Link unprocessable
meip-20211231_def.xml Edgar Link unprocessable
meip-20211231_htm.xml Edgar Link completed
meip-20211231_lab.xml Edgar Link unprocessable
meip-20211231_pre.xml Edgar Link unprocessable
meip-ex31_1.htm Edgar Link pending
meip-ex31_2.htm Edgar Link pending
meip-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending